Drugs / NWY001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05979155 | Jan 2024 → Jan 2026 overdue | neoplasm | Chipscreen Biosciences, Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NWY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05979155 ↗ |
| Route | Intravenous | “intravenously” NCT05979155 ↗ |